Device continues its international expansion, positioning its brand as a benchmark in innovative therapeutic solutions in urology. After taking the leap into the US market in May, the company has signed three new agreements to market Lit-Control® in the United Kingdom, Malta and Algeria. In total, Devicare is now present in 34 countries.

The partners in these countries are the pharmaceutical companies Purple Orchid Health, Vivian Corporation and Pharm and Phyt, respectively. Purple Orchid Health has extensive experience in urology, obstetrics and gynaecology products in the UK market. Vivian Corporation is one of the leading pharmaceutical distributors on the island of Malta with products from Boehringer Ingelheim, Merck, Johnson & Johnson, Pfizer and Roche. Pharm and Phyt is the leading distributor of food supplements and nutraceuticals in Algeria.

“We are proud of this new milestone because more doctors and patients will be able to access the first non-surgical therapeutic treatment for all types of renal lithiasis, with the added value that we are strengthening our presence in Europe and north Africa” explains Miquel González Mut, International Business Development Manager of Devicare.

Would you like to join the project as a small investor?

Devicare currently has an investment round underway on Capital Cell with tickets starting from 1,000 Euros so that small investors and savers can participate in a growing project with potentially high profitability, which improves the quality of life for patients:

https://capitalcell.es/campaign/devicare/